ALDH1A2 and non-small cell lung carcinoma: Further supporting that augmented ALDH activity is a feature of stem cells and chemoresistance in NSCLC, in silico analysis37 of 1570 NSCLC patients showed that high expression of ALDH1A2, but not of ALDH1A1 and ALDH1A3, was associated with poorer prognosis (Supplementary Figure S3G).